Serum GFAP as a biomarker for disease severity in multiple sclerosis

While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on astroglial markers in serum are missing. In our study, glial fibrillary acid protein (GFAP) and NfL were measured in cerebrospinal fluid (CSF) and serum o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports Jg. 8; H. 1; S. 14798 - 7
Hauptverfasser:	Abdelhak, A., Huss, A., Kassubek, J., Tumani, H., Otto, M.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 04.10.2018 Nature Publishing Group Nature Portfolio
Schlagworte:	692/617/375/1666 692/617/375/365 Autoimmune diseases Cerebrospinal fluid Expanded Disability Status Scale (EDSS) GFAP Levels Glial fibrillary acidic protein Glial Fibrillary Acidic Protein (GFAP) Humanities and Social Sciences Lesions Magnetic resonance imaging multidisciplinary Multiple sclerosis Neurological diseases Relapsing-remitting MS (RRMS) Science Science (multidisciplinary) Serum GFAP Serum levels Relapsing-remitting MS (RRMS) Glial Fibrillary Acidic Protein (GFAP) Expanded Disability Status Scale (EDSS) Serum GFAP GFAP Levels
ISSN:	2045-2322, 2045-2322
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on astroglial markers in serum are missing. In our study, glial fibrillary acid protein (GFAP) and NfL were measured in cerebrospinal fluid (CSF) and serum of MS patients and patients with other non-inflammatory neurological diseases (OND) using the Simoa technology. Clinical data like age, gender, expanded disability status scale (EDSS) and MRI findings were correlated to neurochemical markers. We included 80 MS patients: 42 relapsing-remitting MS (RRMS), 38 progressive MS (PMS), as well as 20 OND. Serum GFAP levels were higher in PMS compared to RRMS and OND (p < 0.001, p = 0.02 respectively). Serum GFAP levels correlated with disease severity in the whole MS group and PMS (Spearman-rho = 0.5, p < 0.001 in both groups). Serum GFAP correlated with serum NfL in PMS patients (Spearman-rho = 0.4, p = 0.01). Levels of serum GFAP were higher with increasing MRI-lesion count (p = 0.01). in summary, we report elevated levels of GFAP in the serum of MS patients. Since serum levels of GFAP correlate with the clinical severity scores and MRI lesion count, especially in PMS patients, it might be a suitable disease progression marker.
AbstractList	While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on astroglial markers in serum are missing. In our study, glial fibrillary acid protein (GFAP) and NfL were measured in cerebrospinal fluid (CSF) and serum of MS patients and patients with other non-inflammatory neurological diseases (OND) using the Simoa technology. Clinical data like age, gender, expanded disability status scale (EDSS) and MRI findings were correlated to neurochemical markers. We included 80 MS patients: 42 relapsing-remitting MS (RRMS), 38 progressive MS (PMS), as well as 20 OND. Serum GFAP levels were higher in PMS compared to RRMS and OND (p < 0.001, p = 0.02 respectively). Serum GFAP levels correlated with disease severity in the whole MS group and PMS (Spearman-rho = 0.5, p < 0.001 in both groups). Serum GFAP correlated with serum NfL in PMS patients (Spearman-rho = 0.4, p = 0.01). Levels of serum GFAP were higher with increasing MRI-lesion count (p = 0.01). in summary, we report elevated levels of GFAP in the serum of MS patients. Since serum levels of GFAP correlate with the clinical severity scores and MRI lesion count, especially in PMS patients, it might be a suitable disease progression marker. While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on astroglial markers in serum are missing. In our study, glial fibrillary acid protein (GFAP) and NfL were measured in cerebrospinal fluid (CSF) and serum of MS patients and patients with other non-inflammatory neurological diseases (OND) using the Simoa technology. Clinical data like age, gender, expanded disability status scale (EDSS) and MRI findings were correlated to neurochemical markers. We included 80 MS patients: 42 relapsing-remitting MS (RRMS), 38 progressive MS (PMS), as well as 20 OND. Serum GFAP levels were higher in PMS compared to RRMS and OND (p < 0.001, p = 0.02 respectively). Serum GFAP levels correlated with disease severity in the whole MS group and PMS (Spearman-rho = 0.5, p < 0.001 in both groups). Serum GFAP correlated with serum NfL in PMS patients (Spearman-rho = 0.4, p = 0.01). Levels of serum GFAP were higher with increasing MRI-lesion count (p = 0.01). in summary, we report elevated levels of GFAP in the serum of MS patients. Since serum levels of GFAP correlate with the clinical severity scores and MRI lesion count, especially in PMS patients, it might be a suitable disease progression marker.While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on astroglial markers in serum are missing. In our study, glial fibrillary acid protein (GFAP) and NfL were measured in cerebrospinal fluid (CSF) and serum of MS patients and patients with other non-inflammatory neurological diseases (OND) using the Simoa technology. Clinical data like age, gender, expanded disability status scale (EDSS) and MRI findings were correlated to neurochemical markers. We included 80 MS patients: 42 relapsing-remitting MS (RRMS), 38 progressive MS (PMS), as well as 20 OND. Serum GFAP levels were higher in PMS compared to RRMS and OND (p < 0.001, p = 0.02 respectively). Serum GFAP levels correlated with disease severity in the whole MS group and PMS (Spearman-rho = 0.5, p < 0.001 in both groups). Serum GFAP correlated with serum NfL in PMS patients (Spearman-rho = 0.4, p = 0.01). Levels of serum GFAP were higher with increasing MRI-lesion count (p = 0.01). in summary, we report elevated levels of GFAP in the serum of MS patients. Since serum levels of GFAP correlate with the clinical severity scores and MRI lesion count, especially in PMS patients, it might be a suitable disease progression marker. Abstract While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on astroglial markers in serum are missing. In our study, glial fibrillary acid protein (GFAP) and NfL were measured in cerebrospinal fluid (CSF) and serum of MS patients and patients with other non-inflammatory neurological diseases (OND) using the Simoa technology. Clinical data like age, gender, expanded disability status scale (EDSS) and MRI findings were correlated to neurochemical markers. We included 80 MS patients: 42 relapsing-remitting MS (RRMS), 38 progressive MS (PMS), as well as 20 OND. Serum GFAP levels were higher in PMS compared to RRMS and OND (p < 0.001, p = 0.02 respectively). Serum GFAP levels correlated with disease severity in the whole MS group and PMS (Spearman-rho = 0.5, p < 0.001 in both groups). Serum GFAP correlated with serum NfL in PMS patients (Spearman-rho = 0.4, p = 0.01). Levels of serum GFAP were higher with increasing MRI-lesion count (p = 0.01). in summary, we report elevated levels of GFAP in the serum of MS patients. Since serum levels of GFAP correlate with the clinical severity scores and MRI lesion count, especially in PMS patients, it might be a suitable disease progression marker.
ArticleNumber	14798
Author	Huss, A. Abdelhak, A. Kassubek, J. Tumani, H. Otto, M.
Author_xml	– sequence: 1 givenname: A. orcidid: 0000-0001-9731-4169 surname: Abdelhak fullname: Abdelhak, A. organization: Department of Neurology, University Hospital of Ulm – sequence: 2 givenname: A. surname: Huss fullname: Huss, A. organization: Department of Experimental Neurology, University of Ulm – sequence: 3 givenname: J. surname: Kassubek fullname: Kassubek, J. organization: Department of Neurology, University Hospital of Ulm – sequence: 4 givenname: H. surname: Tumani fullname: Tumani, H. organization: Department of Neurology, University Hospital of Ulm, Speciality Clinic of Neurology Dietenbronn – sequence: 5 givenname: M. orcidid: 0000-0003-4273-4267 surname: Otto fullname: Otto, M. email: markus.otto@uni-ulm.de organization: Department of Neurology, University Hospital of Ulm
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/30287870$$D View this record in MEDLINE/PubMed
BookMark	eNp9Uk1v1DAUtFARLaV_gAOKxIVLwN92LkhVoaVSJZCAs2U7z4uXbLzYSaX-e7ybUtoe6out55l54-d5iQ7GNAJCrwl-TzDTHwonotMtJrpljAjd6mfoiGIuWsooPbh3PkQnpaxxXYJ2nHQv0CHDVCut8BH69B3yvGkuzk-_NbY0tnExbWz-DbkJKTd9LGALNAWuIcfppoljs5mHKW6HWvQD5FRieYWeBzsUOLndj9HP888_zr60V18vLs9Or1ovsZxaaq2WQkmmPRWM8UBVcBxUp3TopdTgBe6kcFqC5w56wTtBdd9b4h1WwrJjdLno9smuzTbH6vTGJBvNvpDyytg8xWrLEOecClxbzXvOeqaVDNZySYQLrguuan1ctLaz20DvYZyyHR6IPrwZ4y-zStdGEkWp4FXg3a1ATn9mKJPZxOJhGOwIaS6GEiI1F0SxCn37CLpOcx7rqPYoTggjO9Sb-47urPz7rAqgC8DXqZcM4Q5CsNmFwiyhMDUUZh8KoytJPyL5ONkppt2r4vA0lS3UUvuMK8j_bT_B-gvyXMpB
CitedBy_id	crossref_primary_10_1111_ahe_12937 crossref_primary_10_1016_j_msard_2023_104854 crossref_primary_10_1177_13524585231198751 crossref_primary_10_1080_10799893_2020_1830109 crossref_primary_10_1016_j_jns_2024_122980 crossref_primary_10_1186_s40659_022_00404_3 crossref_primary_10_1515_cclm_2025_0870 crossref_primary_10_1186_s42466_025_00379_y crossref_primary_10_1080_00207454_2023_2277664 crossref_primary_10_1212_NXI_0000000000200025 crossref_primary_10_1002_acn3_51070 crossref_primary_10_1038_s41582_022_00624_x crossref_primary_10_1080_08820139_2023_2281621 crossref_primary_10_1016_j_ncl_2023_06_008 crossref_primary_10_1007_s11910_022_01227_1 crossref_primary_10_1016_j_jns_2024_122979 crossref_primary_10_1016_j_expneurol_2021_113947 crossref_primary_10_1177_13524585251335521 crossref_primary_10_1017_S1431927621000325 crossref_primary_10_1177_23969873211010069 crossref_primary_10_1177_20552173251372751 crossref_primary_10_1016_j_biopha_2024_116607 crossref_primary_10_1016_j_arr_2024_102247 crossref_primary_10_1097_WCO_0000000000001262 crossref_primary_10_1177_13524585231176732 crossref_primary_10_1038_s41598_024_75290_8 crossref_primary_10_1177_08830738221079476 crossref_primary_10_1212_WNL_0000000000008160 crossref_primary_10_3390_v16121811 crossref_primary_10_1080_10408363_2019_1700903 crossref_primary_10_1186_s12974_024_03315_0 crossref_primary_10_1212_NXI_0000000000200167 crossref_primary_10_1089_neu_2024_0581 crossref_primary_10_1093_brain_awab241 crossref_primary_10_1016_j_ensci_2025_100550 crossref_primary_10_3389_fneur_2025_1627405 crossref_primary_10_52881_gsbdergi_1762684 crossref_primary_10_1007_s00415_020_09917_x crossref_primary_10_3389_fnins_2024_1287228 crossref_primary_10_3390_diagnostics11091522 crossref_primary_10_1002_acn3_52187 crossref_primary_10_1007_s40120_024_00654_1 crossref_primary_10_1515_cclm_2025_0667 crossref_primary_10_1212_NXI_0000000000200052 crossref_primary_10_1016_j_ijbiomac_2025_143884 crossref_primary_10_1038_s41380_023_01976_6 crossref_primary_10_1002_ana_26067 crossref_primary_10_1007_s40263_024_01132_w crossref_primary_10_1016_j_msard_2021_102870 crossref_primary_10_1007_s00415_025_13231_9 crossref_primary_10_1177_13524585221094224 crossref_primary_10_3389_fneur_2021_779890 crossref_primary_10_1177_13524585231188625 crossref_primary_10_1007_s00415_024_12389_y crossref_primary_10_1038_s41467_025_60747_9 crossref_primary_10_3390_ijms22063233 crossref_primary_10_1016_j_msard_2021_103280 crossref_primary_10_1136_jnnp_2022_329933 crossref_primary_10_3390_ijms231810304 crossref_primary_10_1515_cclm_2022_0007 crossref_primary_10_1371_journal_pone_0274565 crossref_primary_10_1016_j_conctc_2020_100574 crossref_primary_10_1016_j_ibneur_2025_04_016 crossref_primary_10_3390_ijms24054375 crossref_primary_10_1016_j_clinbiochem_2025_110980 crossref_primary_10_3390_medicina60071050 crossref_primary_10_1097_YCO_0000000000000851 crossref_primary_10_1002_adhm_202401966 crossref_primary_10_1007_s15016_025_4025_9 crossref_primary_10_1212_NXI_0000000000000998 crossref_primary_10_1111_ene_16323 crossref_primary_10_3390_ijms231911532 crossref_primary_10_3390_ijms26073412 crossref_primary_10_1186_s12882_025_04130_2 crossref_primary_10_1016_j_msard_2023_104998 crossref_primary_10_3390_ijms241311130 crossref_primary_10_1016_j_conctc_2024_101279 crossref_primary_10_1080_14737159_2024_2334849 crossref_primary_10_1515_cclm_2022_0480 crossref_primary_10_1002_alz_12510 crossref_primary_10_1016_j_bios_2020_112774 crossref_primary_10_3389_fneur_2023_1137998 crossref_primary_10_3389_fneur_2023_1209749 crossref_primary_10_1177_13524585221137697 crossref_primary_10_1007_s13311_022_01267_y crossref_primary_10_1080_15287394_2020_1850381 crossref_primary_10_1099_jgv_0_001764 crossref_primary_10_1212_NXI_0000000000001151 crossref_primary_10_1016_j_cell_2023_03_008 crossref_primary_10_3390_ijms25168751 crossref_primary_10_4081_ejh_2021_3276 crossref_primary_10_1038_s41582_021_00616_3 crossref_primary_10_1007_s00415_023_11817_9 crossref_primary_10_4103_1673_5374_391329 crossref_primary_10_1111_ene_70052 crossref_primary_10_17116_jnevro202412410180 crossref_primary_10_1080_14789450_2020_1745069 crossref_primary_10_3389_fneur_2022_865730 crossref_primary_10_3390_jcm12134274 crossref_primary_10_1016_j_msard_2023_104695 crossref_primary_10_1016_j_jneuroim_2021_577541 crossref_primary_10_3390_ijms241311112 crossref_primary_10_1016_j_jneumeth_2021_109281 crossref_primary_10_1515_revneuro_2020_0145 crossref_primary_10_1007_s00401_019_01980_7 crossref_primary_10_1177_13524585231219131 crossref_primary_10_1186_s12974_019_1674_2 crossref_primary_10_1093_brain_awab304 crossref_primary_10_3389_fneur_2023_1233192 crossref_primary_10_1038_s41598_020_71060_4 crossref_primary_10_1111_jnc_16226 crossref_primary_10_3389_fneur_2020_628542 crossref_primary_10_1212_NXI_0000000000000885 crossref_primary_10_1186_s13195_021_00793_9 crossref_primary_10_3390_biomedicines10081869 crossref_primary_10_1007_s10072_024_07790_4 crossref_primary_10_3390_ijms25158132 crossref_primary_10_1002_ana_27096 crossref_primary_10_3233_JAD_200755 crossref_primary_10_1016_j_jns_2022_120385 crossref_primary_10_1016_j_jneuroim_2025_578613 crossref_primary_10_1080_14737175_2025_2506462 crossref_primary_10_3389_fnmol_2023_1210091 crossref_primary_10_1007_s00415_023_11676_4 crossref_primary_10_1177_11772719211013352 crossref_primary_10_3389_fimmu_2025_1543649 crossref_primary_10_1007_s00415_023_12021_5 crossref_primary_10_1016_j_msard_2025_106410 crossref_primary_10_1016_j_neurobiolaging_2021_02_012 crossref_primary_10_1186_s12014_024_09466_9 crossref_primary_10_1038_s41598_020_67934_2 crossref_primary_10_1111_jon_13232 crossref_primary_10_1136_jnnp_2025_335831 crossref_primary_10_1016_j_bionps_2023_100075 crossref_primary_10_1016_j_cca_2023_117471 crossref_primary_10_1136_jnnp_2022_329221 crossref_primary_10_1136_jnnp_2023_332251 crossref_primary_10_1177_20552173251370830 crossref_primary_10_3389_fneur_2019_00280 crossref_primary_10_1007_s11055_025_01803_1 crossref_primary_10_3389_fneur_2024_1382468 crossref_primary_10_1136_practneurol_2018_002000 crossref_primary_10_1080_13543784_2025_2472240 crossref_primary_10_1111_ene_70222 crossref_primary_10_1186_s12883_020_01765_6 crossref_primary_10_1212_NXI_0000000000200064 crossref_primary_10_1016_j_msard_2025_106674 crossref_primary_10_1016_j_intimp_2022_108624 crossref_primary_10_3390_ijms231810946 crossref_primary_10_1016_j_msard_2024_106150 crossref_primary_10_1002_eji_202250228 crossref_primary_10_1016_j_lanepe_2024_101009 crossref_primary_10_1007_s00415_025_13223_9 crossref_primary_10_1038_s41598_025_95229_x crossref_primary_10_1136_bmjopen_2020_043699 crossref_primary_10_1515_cclm_2022_0646 crossref_primary_10_1177_13524585211010082 crossref_primary_10_3390_ijms26010298 crossref_primary_10_1177_02841851241305738 crossref_primary_10_1016_j_msard_2021_103219 crossref_primary_10_1212_NXI_0000000000200078 crossref_primary_10_1016_j_medj_2024_09_011 crossref_primary_10_1016_j_preteyeres_2022_101134 crossref_primary_10_3389_fneur_2019_01232 crossref_primary_10_3390_biomedicines8090312 crossref_primary_10_3389_fmolb_2023_1175230 crossref_primary_10_1212_WNL_0000000000012109 crossref_primary_10_1016_j_msard_2024_105644 crossref_primary_10_1055_a_2335_0149 crossref_primary_10_1515_cclm_2023_1256 crossref_primary_10_1002_acn3_51969 crossref_primary_10_1016_j_talanta_2023_125597 crossref_primary_10_1016_j_msard_2021_102810 crossref_primary_10_1111_ene_70207 crossref_primary_10_1002_acn3_51045 crossref_primary_10_1016_j_jaci_2021_09_010 crossref_primary_10_1186_s12974_021_02138_7 crossref_primary_10_1016_j_pharmthera_2020_107669 crossref_primary_10_3390_ijms23063383 crossref_primary_10_1016_j_neurot_2025_e00588 crossref_primary_10_1136_bmjno_2021_000143 crossref_primary_10_1016_j_neurot_2025_e00582 crossref_primary_10_1111_pcn_13610 crossref_primary_10_3389_fneur_2020_00608 crossref_primary_10_3390_ijms232113466 crossref_primary_10_1136_jnnp_2022_330412 crossref_primary_10_3390_diagnostics14171993 crossref_primary_10_1186_s40364_021_00325_5 crossref_primary_10_1016_j_msard_2022_103535 crossref_primary_10_1038_s41598_022_11557_2 crossref_primary_10_1016_j_jneuroim_2023_578064 crossref_primary_10_1016_j_msard_2024_105517 crossref_primary_10_1038_s41398_020_01137_1 crossref_primary_10_1186_s13287_021_02563_8 crossref_primary_10_1002_jnr_24922 crossref_primary_10_1016_j_cca_2025_120248 crossref_primary_10_1186_s40478_020_01086_2 crossref_primary_10_1016_j_bbagen_2022_130207 crossref_primary_10_1007_s00415_021_10489_7 crossref_primary_10_3390_ijms25052483 crossref_primary_10_1177_20552173241274567 crossref_primary_10_1016_j_heliyon_2024_e28085 crossref_primary_10_1080_1744666X_2023_2148657 crossref_primary_10_3389_fneur_2021_666868
Cites_doi	10.1515/CCLM.2001.051 10.1371/journal.pone.0007624 10.1515/cclm-2015-1195 10.1007/s00401-009-0619-8 10.1046/j.1469-7580.2002.00064.x 10.1007/s10072-012-0974-4 10.1016/j.jneuroim.2016.08.004 10.1089/neu.2015.4333 10.1016/j.immuni.2017.06.006 10.1002/ana.24954 10.1002/ana.22366 10.1212/01.WNL.0000098880.19793.B6 10.1016/j.neulet.2017.07.050 10.1016/0022-510X(95)00152-R 10.1016/j.expneurol.2013.12.003 10.1212/WNL.0b013e3181c47cc2 10.1111/ane.12239 10.3390/ijms160817565 10.1212/01.WNL.0000142988.49341.D1 10.1212/WNL.0000000000003653 10.1016/S1474-4422(17)30470-2 10.1002/pmic.200300456 10.1212/WNL.0000000000004683 10.3389/fneur.2015.00180 10.1212/01.wnl.0000313377.49555.2e 10.1007/s00415-010-5863-2 10.1177/1352458514549397 10.1093/brain/awf165 10.1038/nature21029 10.1177/1352458511433303 10.1046/j.1365-2990.2003.00491.x 10.1177/1352458517690618 10.1016/S1474-4422(14)70256-X 10.1038/nrneurol.2012.168 10.3389/fneur.2017.00234
ContentType	Journal Article
Copyright	The Author(s) 2018 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s) 2018 – notice: 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	C6C AAYXX CITATION NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA
DOI	10.1038/s41598-018-33158-8
DatabaseName	Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Science Database (ProQuest) Biological Science Database (ProQuest) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Publicly Available Content Database CrossRef MEDLINE - Academic PubMed
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
EISSN	2045-2322
EndPage	7
ExternalDocumentID	oai_doaj_org_article_1bbb7f48a84d43d3876faa4615bfb9fb PMC6172254 30287870 10_1038_s41598_018_33158_8
Genre	Journal Article
GroupedDBID	0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS EJD ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IPNFZ KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RIG RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFFHD AFPKN CITATION PHGZM PHGZT PJZUB PPXIY PQGLB NPM 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c606t-2aa8657638c25334f27fb4e7978fd668ec50965b86ec4bed549528dda1cb075a3
IEDL.DBID	M7P
ISICitedReferencesCount	225
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000446325500010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2045-2322
IngestDate	Fri Oct 03 12:45:36 EDT 2025 Tue Nov 04 02:00:54 EST 2025 Fri Sep 05 12:06:35 EDT 2025 Tue Oct 07 08:10:51 EDT 2025 Thu Jan 02 23:04:07 EST 2025 Sat Nov 29 02:11:25 EST 2025 Tue Nov 18 21:47:46 EST 2025 Fri Feb 21 02:38:26 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Relapsing-remitting MS (RRMS) Glial Fibrillary Acidic Protein (GFAP) Expanded Disability Status Scale (EDSS) Serum GFAP GFAP Levels
Language	English
License	Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c606t-2aa8657638c25334f27fb4e7978fd668ec50965b86ec4bed549528dda1cb075a3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0001-9731-4169 0000-0003-4273-4267
OpenAccessLink	https://www.proquest.com/docview/2116411313?pq-origsite=%requestingapplication%
PMID	30287870
PQID	2116411313
PQPubID	2041939
PageCount	7
ParticipantIDs	doaj_primary_oai_doaj_org_article_1bbb7f48a84d43d3876faa4615bfb9fb pubmedcentral_primary_oai_pubmedcentral_nih_gov_6172254 proquest_miscellaneous_2116845173 proquest_journals_2116411313 pubmed_primary_30287870 crossref_primary_10_1038_s41598_018_33158_8 crossref_citationtrail_10_1038_s41598_018_33158_8 springer_journals_10_1038_s41598_018_33158_8
PublicationCentury	2000
PublicationDate	2018-10-04
PublicationDateYYYYMMDD	2018-10-04
PublicationDate_xml	– month: 10 year: 2018 text: 2018-10-04 day: 04
PublicationDecade	2010
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Scientific reports
PublicationTitleAbbrev	Sci Rep
PublicationTitleAlternate	Sci Rep
PublicationYear	2018
Publisher	Nature Publishing Group UK Nature Publishing Group Nature Portfolio
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio
References	Petzold (CR4) 2002; 125 Liddelow (CR3) 2017; 541 Bogoslovsky (CR11) 2017; 34 Reiber, Otto, Trendelenburg, Wormek (CR36) 2001; 39 Liddelow, Barres (CR30) 2017; 46 Martinez (CR6) 2015; 21 Abbott (CR27) 2002; 200 Tallantyre (CR29) 2008; 70 Kuhle (CR19) 2017; 88 Burman (CR17) 2014; 130 Holley, Gveric, Newcombe, Cuzner, Gutowski (CR25) 2003; 29 Manouchehrinia (CR34) 2017; 23 Norgren (CR13) 2004; 63 Avsar (CR10) 2012; 18 Malmestrom, Haghighi, Rosengren, Andersen, Lycke (CR15) 2003; 61 Lassmann, van Horssen, Mahad (CR24) 2012; 8 Thompson (CR32) 2017 Mahad, Trapp, Lassmann (CR22) 2015; 14 Teunissen (CR35) 2009; 73 Mane-Martinez (CR7) 2016; 299 Fog (CR28) 1964; 40 Abdelhak, Weber, Tumani (CR23) 2017; 8 Axelsson (CR5) 2011; 258 Abdelhak (CR12) 2015; 16 Kassubek (CR8) 2017; 657 Novakova (CR31) 2017; 89 Sofroniew, Vinters (CR26) 2010; 119 Rosengren, Lycke, Andersen (CR14) 1995; 133 Disanto (CR18) 2017 Polman (CR33) 2011; 69 Porchet (CR21) 2003; 3 Linker (CR9) 2009; 4 Lassmann (CR2) 2014; 262 Correale, Farez (CR1) 2015; 6 Kuhle (CR20) 2016; 54 Madeddu (CR16) 2013; 34 SA Liddelow (33158_CR3) 2017; 541 A Abdelhak (33158_CR12) 2015; 16 R Kassubek (33158_CR8) 2017; 657 DH Mahad (33158_CR22) 2015; 14 G Disanto (33158_CR18) 2017 N Norgren (33158_CR13) 2004; 63 J Correale (33158_CR1) 2015; 6 R Porchet (33158_CR21) 2003; 3 SA Liddelow (33158_CR30) 2017; 46 CH Polman (33158_CR33) 2011; 69 T Avsar (33158_CR10) 2012; 18 J Kuhle (33158_CR19) 2017; 88 M Axelsson (33158_CR5) 2011; 258 T Bogoslovsky (33158_CR11) 2017; 34 R Madeddu (33158_CR16) 2013; 34 NJ Abbott (33158_CR27) 2002; 200 H Lassmann (33158_CR24) 2012; 8 MV Sofroniew (33158_CR26) 2010; 119 L Novakova (33158_CR31) 2017; 89 EC Tallantyre (33158_CR29) 2008; 70 JE Holley (33158_CR25) 2003; 29 MA Mane-Martinez (33158_CR7) 2016; 299 A Manouchehrinia (33158_CR34) 2017; 23 LE Rosengren (33158_CR14) 1995; 133 J Kuhle (33158_CR20) 2016; 54 A Abdelhak (33158_CR23) 2017; 8 J Burman (33158_CR17) 2014; 130 T Fog (33158_CR28) 1964; 40 CE Teunissen (33158_CR35) 2009; 73 H Lassmann (33158_CR2) 2014; 262 AJ Thompson (33158_CR32) 2017 RA Linker (33158_CR9) 2009; 4 H Reiber (33158_CR36) 2001; 39 MA Martinez (33158_CR6) 2015; 21 A Petzold (33158_CR4) 2002; 125 C Malmestrom (33158_CR15) 2003; 61 31164658 - Sci Rep. 2019 Jun 5;9(1):8433
References_xml	– volume: 39 start-page: 324 year: 2001 end-page: 332 ident: CR36 article-title: Reporting cerebrospinal fluid data: knowledge base and interpretation software publication-title: Clin. Chem. Lab. Med. doi: 10.1515/CCLM.2001.051 – volume: 4 start-page: e7624 year: 2009 ident: CR9 article-title: Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage publication-title: PloS one doi: 10.1371/journal.pone.0007624 – volume: 54 start-page: 1655 year: 2016 end-page: 1661 ident: CR20 article-title: Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa publication-title: Clin. Chem. Lab. Med. doi: 10.1515/cclm-2015-1195 – volume: 119 start-page: 7 year: 2010 end-page: 35 ident: CR26 article-title: Astrocytes: biology and pathology publication-title: Acta Neuropathol doi: 10.1007/s00401-009-0619-8 – volume: 200 start-page: 629 year: 2002 end-page: 638 ident: CR27 article-title: Astrocyte-endothelial interactions and blood-brain barrier permeability publication-title: J. Anat. doi: 10.1046/j.1469-7580.2002.00064.x – volume: 34 start-page: 181 year: 2013 end-page: 186 ident: CR16 article-title: Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis publication-title: Neurol. Sci doi: 10.1007/s10072-012-0974-4 – volume: 299 start-page: 112 year: 2016 end-page: 117 ident: CR7 article-title: Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis publication-title: Journal of neuroimmunology doi: 10.1016/j.jneuroim.2016.08.004 – volume: 34 start-page: 66 year: 2017 end-page: 73 ident: CR11 article-title: Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid beta up to 90 Days after Traumatic Brain Injury publication-title: J. Neurotrauma doi: 10.1089/neu.2015.4333 – volume: 46 start-page: 957 year: 2017 end-page: 967 ident: CR30 article-title: Reactive Astrocytes: Production, Function, and Therapeutic Potential publication-title: Immunity doi: 10.1016/j.immuni.2017.06.006 – year: 2017 ident: CR18 article-title: Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis publication-title: Annals of neurology doi: 10.1002/ana.24954 – volume: 69 start-page: 292 year: 2011 end-page: 302 ident: CR33 article-title: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria publication-title: Annals of neurology doi: 10.1002/ana.22366 – volume: 61 start-page: 1720 year: 2003 end-page: 1725 ident: CR15 article-title: Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS publication-title: Neurology doi: 10.1212/01.WNL.0000098880.19793.B6 – volume: 657 start-page: 166 year: 2017 end-page: 170 ident: CR8 article-title: GFAP in early multiple sclerosis: A biomarker for inflammation publication-title: Neurosci Lett. doi: 10.1016/j.neulet.2017.07.050 – volume: 133 start-page: 61 year: 1995 end-page: 65 ident: CR14 article-title: Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit publication-title: Journal of the neurological sciences doi: 10.1016/0022-510X(95)00152-R – volume: 262 start-page: 2 issue: Pt A year: 2014 end-page: 7 ident: CR2 article-title: Multiple sclerosis: lessons from molecular neuropathology publication-title: Exp. Neurol. doi: 10.1016/j.expneurol.2013.12.003 – volume: 73 start-page: 1914 year: 2009 end-page: 1922 ident: CR35 article-title: A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking publication-title: Neurology doi: 10.1212/WNL.0b013e3181c47cc2 – volume: 130 start-page: 81 year: 2014 end-page: 89 ident: CR17 article-title: Assessing tissue damage in multiple sclerosis: a biomarker approach publication-title: Acta Neurol Scand doi: 10.1111/ane.12239 – volume: 16 start-page: 17565 year: 2015 end-page: 17588 ident: CR12 article-title: Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis? publication-title: In.t J. Mol. Sci. doi: 10.3390/ijms160817565 – volume: 63 start-page: 1586 year: 2004 end-page: 1590 ident: CR13 article-title: Neurofilament and glial fibrillary acidic protein in multiple sclerosis publication-title: Neurology doi: 10.1212/01.WNL.0000142988.49341.D1 – volume: 88 start-page: 826 year: 2017 end-page: 831 ident: CR19 article-title: Serum neurofilament is associated with progression of brain atrophy and disability in early MS publication-title: Neurology doi: 10.1212/WNL.0000000000003653 – year: 2017 ident: CR32 article-title: Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria publication-title: The Lancet. Neurology doi: 10.1016/S1474-4422(17)30470-2 – volume: 3 start-page: 1476 year: 2003 end-page: 1485 ident: CR21 article-title: Analysis of glial acidic fibrillary protein in the human entorhinal cortex during aging and in Alzheimer’s disease publication-title: Proteomics doi: 10.1002/pmic.200300456 – volume: 89 start-page: 2230 year: 2017 end-page: 2237 ident: CR31 article-title: Monitoring disease activity in multiple sclerosis using serum neurofilament light protein publication-title: Neurology doi: 10.1212/WNL.0000000000004683 – volume: 6 start-page: 180 year: 2015 ident: CR1 article-title: The Role of Astrocytes in Multiple Sclerosis Progression publication-title: Front. Neurol. doi: 10.3389/fneur.2015.00180 – volume: 70 start-page: 2076 year: 2008 end-page: 2078 ident: CR29 article-title: Demonstrating the perivascular distribution of MS lesions with 7-Tesla MRI publication-title: Neurology doi: 10.1212/01.wnl.0000313377.49555.2e – volume: 258 start-page: 882 year: 2011 end-page: 888 ident: CR5 article-title: Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis publication-title: Journal of neurology doi: 10.1007/s00415-010-5863-2 – volume: 21 start-page: 550 year: 2015 end-page: 561 ident: CR6 article-title: Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis publication-title: Multiple sclerosis doi: 10.1177/1352458514549397 – volume: 125 start-page: 1462 year: 2002 end-page: 1473 ident: CR4 article-title: Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations publication-title: Brain: a journal of neurology doi: 10.1093/brain/awf165 – volume: 541 start-page: 481 year: 2017 end-page: 487 ident: CR3 article-title: Neurotoxic reactive astrocytes are induced by activated microglia publication-title: Nature doi: 10.1038/nature21029 – volume: 18 start-page: 1081 year: 2012 end-page: 1091 ident: CR10 article-title: Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis publication-title: Multiple sclerosis doi: 10.1177/1352458511433303 – volume: 29 start-page: 434 year: 2003 end-page: 444 ident: CR25 article-title: Astrocyte characterization in the multiple sclerosis glial scar publication-title: Neuropathology and applied neurobiology doi: 10.1046/j.1365-2990.2003.00491.x – volume: 23 start-page: 1938 year: 2017 end-page: 1946 ident: CR34 article-title: Age Related Multiple Sclerosis Severity Score: Disability ranked by age publication-title: Multiple sclerosis doi: 10.1177/1352458517690618 – volume: 14 start-page: 183 year: 2015 end-page: 193 ident: CR22 article-title: Pathological mechanisms in progressive multiple sclerosis publication-title: The Lancet. Neurology doi: 10.1016/S1474-4422(14)70256-X – volume: 40 start-page: 19 issue: SUPPL 10 year: 1964 end-page: 15 ident: CR28 article-title: On the Vessel-Plaque Relationships in the Brain in Multiple Sclerosis publication-title: Acta. Neurol. Scand. Suppl. – volume: 8 start-page: 647 year: 2012 end-page: 656 ident: CR24 article-title: Progressive multiple sclerosis: pathology and pathogenesis publication-title: Nature reviews. Neurology doi: 10.1038/nrneurol.2012.168 – volume: 8 start-page: 234 year: 2017 ident: CR23 article-title: Primary Progressive Multiple Sclerosis: Putting Together the Puzzle publication-title: Front Neurol doi: 10.3389/fneur.2017.00234 – volume: 125 start-page: 1462 year: 2002 ident: 33158_CR4 publication-title: Brain: a journal of neurology doi: 10.1093/brain/awf165 – volume: 69 start-page: 292 year: 2011 ident: 33158_CR33 publication-title: Annals of neurology doi: 10.1002/ana.22366 – volume: 46 start-page: 957 year: 2017 ident: 33158_CR30 publication-title: Immunity doi: 10.1016/j.immuni.2017.06.006 – volume: 18 start-page: 1081 year: 2012 ident: 33158_CR10 publication-title: Multiple sclerosis doi: 10.1177/1352458511433303 – volume: 4 start-page: e7624 year: 2009 ident: 33158_CR9 publication-title: PloS one doi: 10.1371/journal.pone.0007624 – volume: 299 start-page: 112 year: 2016 ident: 33158_CR7 publication-title: Journal of neuroimmunology doi: 10.1016/j.jneuroim.2016.08.004 – volume: 6 start-page: 180 year: 2015 ident: 33158_CR1 publication-title: Front. Neurol. doi: 10.3389/fneur.2015.00180 – volume: 16 start-page: 17565 year: 2015 ident: 33158_CR12 publication-title: In.t J. Mol. Sci. doi: 10.3390/ijms160817565 – volume: 39 start-page: 324 year: 2001 ident: 33158_CR36 publication-title: Clin. Chem. Lab. Med. doi: 10.1515/CCLM.2001.051 – year: 2017 ident: 33158_CR32 publication-title: The Lancet. Neurology doi: 10.1016/S1474-4422(17)30470-2 – volume: 21 start-page: 550 year: 2015 ident: 33158_CR6 publication-title: Multiple sclerosis doi: 10.1177/1352458514549397 – volume: 200 start-page: 629 year: 2002 ident: 33158_CR27 publication-title: J. Anat. doi: 10.1046/j.1469-7580.2002.00064.x – volume: 70 start-page: 2076 year: 2008 ident: 33158_CR29 publication-title: Neurology doi: 10.1212/01.wnl.0000313377.49555.2e – volume: 63 start-page: 1586 year: 2004 ident: 33158_CR13 publication-title: Neurology doi: 10.1212/01.WNL.0000142988.49341.D1 – volume: 133 start-page: 61 year: 1995 ident: 33158_CR14 publication-title: Journal of the neurological sciences doi: 10.1016/0022-510X(95)00152-R – volume: 130 start-page: 81 year: 2014 ident: 33158_CR17 publication-title: Acta Neurol Scand doi: 10.1111/ane.12239 – volume: 119 start-page: 7 year: 2010 ident: 33158_CR26 publication-title: Acta Neuropathol doi: 10.1007/s00401-009-0619-8 – volume: 657 start-page: 166 year: 2017 ident: 33158_CR8 publication-title: Neurosci Lett. doi: 10.1016/j.neulet.2017.07.050 – volume: 34 start-page: 66 year: 2017 ident: 33158_CR11 publication-title: J. Neurotrauma doi: 10.1089/neu.2015.4333 – volume: 34 start-page: 181 year: 2013 ident: 33158_CR16 publication-title: Neurol. Sci doi: 10.1007/s10072-012-0974-4 – volume: 89 start-page: 2230 year: 2017 ident: 33158_CR31 publication-title: Neurology doi: 10.1212/WNL.0000000000004683 – volume: 262 start-page: 2 issue: Pt A year: 2014 ident: 33158_CR2 publication-title: Exp. Neurol. doi: 10.1016/j.expneurol.2013.12.003 – volume: 258 start-page: 882 year: 2011 ident: 33158_CR5 publication-title: Journal of neurology doi: 10.1007/s00415-010-5863-2 – volume: 29 start-page: 434 year: 2003 ident: 33158_CR25 publication-title: Neuropathology and applied neurobiology doi: 10.1046/j.1365-2990.2003.00491.x – volume: 541 start-page: 481 year: 2017 ident: 33158_CR3 publication-title: Nature doi: 10.1038/nature21029 – volume: 8 start-page: 647 year: 2012 ident: 33158_CR24 publication-title: Nature reviews. Neurology doi: 10.1038/nrneurol.2012.168 – volume: 61 start-page: 1720 year: 2003 ident: 33158_CR15 publication-title: Neurology doi: 10.1212/01.WNL.0000098880.19793.B6 – volume: 88 start-page: 826 year: 2017 ident: 33158_CR19 publication-title: Neurology doi: 10.1212/WNL.0000000000003653 – volume: 23 start-page: 1938 year: 2017 ident: 33158_CR34 publication-title: Multiple sclerosis doi: 10.1177/1352458517690618 – year: 2017 ident: 33158_CR18 publication-title: Annals of neurology doi: 10.1002/ana.24954 – volume: 54 start-page: 1655 year: 2016 ident: 33158_CR20 publication-title: Clin. Chem. Lab. Med. doi: 10.1515/cclm-2015-1195 – volume: 8 start-page: 234 year: 2017 ident: 33158_CR23 publication-title: Front Neurol doi: 10.3389/fneur.2017.00234 – volume: 73 start-page: 1914 year: 2009 ident: 33158_CR35 publication-title: Neurology doi: 10.1212/WNL.0b013e3181c47cc2 – volume: 3 start-page: 1476 year: 2003 ident: 33158_CR21 publication-title: Proteomics doi: 10.1002/pmic.200300456 – volume: 40 start-page: 19 issue: SUPPL 10 year: 1964 ident: 33158_CR28 publication-title: Acta. Neurol. Scand. Suppl. – volume: 14 start-page: 183 year: 2015 ident: 33158_CR22 publication-title: The Lancet. Neurology doi: 10.1016/S1474-4422(14)70256-X – reference: 31164658 - Sci Rep. 2019 Jun 5;9(1):8433
SSID	ssj0000529419
Score	2.6246018
Snippet	While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on astroglial... Abstract While neurofilament light chain (NfL) measurement in serum is a well-established marker of neuroaxonal damage in multiple sclerosis (MS), data on...
SourceID	doaj pubmedcentral proquest pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	14798
SubjectTerms	692/617/375/1666 692/617/375/365 Autoimmune diseases Cerebrospinal fluid Expanded Disability Status Scale (EDSS) GFAP Levels Glial fibrillary acidic protein Glial Fibrillary Acidic Protein (GFAP) Humanities and Social Sciences Lesions Magnetic resonance imaging multidisciplinary Multiple sclerosis Neurological diseases Relapsing-remitting MS (RRMS) Science Science (multidisciplinary) Serum GFAP Serum levels
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB5CaKGX0qQv54UCubUmlSVb42OadttDCDm0JTchyRJdaJyw3i3k32ckebfZPi-92rIZ5qH5Bo2-ATgSGJSrlSlFIPgmXV2VhlBsaUPjkACqa1O3-5czdX6Ol5ftxb1RX7EnLNMDZ8Udc2utChINyk6KTlD0BmMkJWIbbBts3H0J9dwrpjKrd9VK3o63ZN4IPB4oU8XbZBxLIXiNJa5lokTY_zuU-Wuz5E8npikRTZ7A4xFBspMs-RZs-H4bHuaZkrdP4R1F_-KKfZicXDAzMMPiBfvYgzNjhE_ZeCDDKCH6OLeOTXu2bCpkA_2QZJ0Oz-Dz5P2n04_lOCqhdFSBzMvKGGyodBDoqni5NlQqWOkV1Yihaxr0LtG8WGy8k9Z3VBXWFXad4c4SaDDiOWz2171_CayrQkugiWMTWmkCWczXnYpUdFSLkV0L4Eu1aTfyiMdxFt90Os8WqLOqNalaJ1VrLODV6pubzKLx19VvozVWKyMDdnpAfqFHv9D_8osC9pa21GNYDpqq3UZyLrgo4HD1mgIqnpKY3l8v8hqUNVe05kU2_UoSQWgs7nAFqDWnWBN1_U0__ZpIuyNSpGK8gNdL9_kh1p9VsfM_VLELj6ro97HtQe7B5ny28PvwwH2fT4fZQQqcOwo5GfE priority: 102 providerName: Directory of Open Access Journals
Title	Serum GFAP as a biomarker for disease severity in multiple sclerosis
URI	https://link.springer.com/article/10.1038/s41598-018-33158-8 https://www.ncbi.nlm.nih.gov/pubmed/30287870 https://www.proquest.com/docview/2116411313 https://www.proquest.com/docview/2116845173 https://pubmed.ncbi.nlm.nih.gov/PMC6172254 https://doaj.org/article/1bbb7f48a84d43d3876faa4615bfb9fb
Volume	8
WOSCitedRecordID	wos000446325500010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M7P dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: 7X7 dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: PIMPY dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M2P dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RFiQuvB-BsjISN4hax07snFALXUCiqwgBWk6W7diwEmTLZheJf8_YeVTLoxcuOcROZHtmPN94xjMAT5j0wuZCp8wjfOM2z1KNKDY1vrASAaotY7T7x7diNpPzeVn1B25tH1Y57Ilxo66XNpyRH6ChUnBKGWXPz76noWpU8K72JTR2YC9kSWAxdK8az1iCF4vTsr8rc8jkQYv6KtwpozJljOYylVv6KKbt_xvW_DNk8je_aVRH0-v_O5EbcK0HouSo45ybcMk1t-BKV5ry5214iZvI5ht5NT2qiG6JJuGefgjlWRGEuaT36xDUqy6UvyOLhgyxiaTFH-JkF-0d-DA9ef_iddpXXEgtGjLrNNNaFmiBMGmzcEfXZ8Ib7gSamr4uCulszBZjZOEsN65G4zLPZF1rag1iD83uwm6zbNx9IHXmS8ReVBa-5Noj4V1ei5DRDk06ZI8E6LDuyvbpyENVjK8qusWZVB2tFNJKRVopmcDT8ZuzLhnHhb2PAznHniGRdnyxXH1WvVwqaowRnkstec1ZzVA5eK054jzjTelNAvsDFVUv3a06J2ECj8dmlMvgbNGNW266PpLnVGCfex3vjCNhCOrCRpmA2OKqraFutzSLLzH3dwCcaNMn8Gzgv_Nh_XspHlw8i4dwNQsiEeIi-D7srlcb9wgu2x_rRbuawI6Yi_iUE9g7PplV7ybx6AKfp1k1iTKHLdWb0-rTL93eLY8
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VLQguvAuBAkaCE0StH0mcA0KFsnTV7WoPBZWTsR0bVoJs2eyC-qf4jYzz2Gp59NYD18SJHOebmW884xmAJ1z6zCaZjrlH-iZswmKNLDY2PrUSCarN62z398NsNJJHR_l4DX52Z2FCWmWnE2tFXUxt2CPfQkclFZRyyl8ef4tD16gQXe1aaDSw2HcnP9Blq14MdvH_PmWs_-bw9V7cdhWILZL1ecy0limybC4tC-dQPcu8ES5Dd8oXaSqdrSuiGJk6K4wr0IFKmCwKTa1B-6o5vvcCrAsEu-zB-nhwMP6w3NUJcTNB8_Z0zjaXWxVayHCKjcqYc5rIWK5YwLpRwN_Y7Z9Jmr9FamsD2L_2vy3ddbjaUm2y08jGDVhz5U241DTfPLkFu6gmF1_J2_7OmOiKaBIqEYRkpRlBIk_ayBVB5uBCgz8yKUmXfUkqfCEu7qS6De_O5RM2oFdOS3cXSMF8juySytTnQnuEtkuKLNTsQ6cVBSAC2v1nZduC66HvxxdVB_65VA02FGJD1dhQMoJny2eOm3IjZ45-FeCzHBlKhdcXprNPqtU8ihpjMi-klqIQvOBo_rzWApms8Sb3JoLNDjWq1V-VOoVMBI-Xt1HzhHCSLt100YyRIqEZjrnTYHU5E460NZiCCLIVFK9MdfVOOflcVzcPlJolIoLnHd5Pp_Xvpbh39lc8gst7hwdDNRyM9u_DFRbEMWSBiE3ozWcL9wAu2u_zSTV72Eo0gY_nLQm_AIQ9hH0
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6V8hAX3o9AASPBCaLFsRM7B4QKy0LVarUHQL0Z27HblSBbNrug_jV-HWMn2Wp59NYD18SJHOebmW884xmAJ0x6YXOhU-aRvnGbZ6lGFpsaX1iJBNWWMdv9054Yj-X-fjnZgJ_9WZiQVtnrxKioq5kNe-QDdFQKTimjbOC7tIjJcPTq6FsaOkiFSGvfTqOFyK47_oHuW_NyZ4j_-mmWjd5-ePM-7ToMpBaJ-yLNtJYFMm4mbRbOpPpMeMOdQNfKV0UhnY3VUYwsnOXGVehM5ZmsKk2tQVurGb73HJwXoWh5TBucrPZ3QgSN07I7p_OCyUGDtjKcZ6MyZYzmMpVrtjC2DPgbz_0zXfO3mG00haOr__MiXoMrHQEn263EXIcNV9-Ai21LzuObMETlufxK3o22J0Q3RJNQnyCkMM0J0nvSxbMI8gkX2v6RaU36nEzS4AtxoafNLfh4Jp9wGzbrWe3uAqkyXyLnpLLwJdceAe_ySoRKfujKolgkQPt_rmxXhj10A_miYjoAk6rFiUKcqIgTJRN4tnrmqC1Ccuro1wFKq5GhgHi8MJsfqE4fKWqMEZ5LLXnFWcXQKHqtEce58ab0JoGtHkGq02qNOoFPAo9Xt1EfhSCTrt1s2Y6RPKcCx9xpcbuaCUMyGwxEAmIN0WtTXb9TTw9jzfNAtLOcJ_C8x_7JtP69FPdO_4pHcAnhr_Z2xrv34XIWJDOkhvAt2FzMl-4BXLDfF9Nm_jCKNoHPZy0GvwD6dou8
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+GFAP+as+a+biomarker+for+disease+severity+in+multiple+sclerosis&rft.jtitle=Scientific+reports&rft.au=Abdelhak%2C+A&rft.au=Huss%2C+A&rft.au=Kassubek%2C+J&rft.au=Tumani%2C+H&rft.date=2018-10-04&rft.pub=Nature+Publishing+Group&rft.eissn=2045-2322&rft.volume=8&rft.spage=1&rft.epage=7&rft_id=info:doi/10.1038%2Fs41598-018-33158-8&rft.externalDBID=HAS_PDF_LINK
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon